Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0QU0H
|
|||
| Drug Name |
OMS721
|
|||
| Indication | Atypical hemolytic uremic syndrome [ICD-11: 3A10.Y] | Phase 3 | [1] | |
| Glomerulonephritis [ICD-11: 5D00.Y] | Phase 2 | [2] | ||
| Lupus [ICD-11: 4A40; ICD-9: 583.81] | Phase 2 | [2] | ||
| Thrombotic microangiopathy [ICD-11: 3B65; ICD-10: M31.1] | Phase 2 | [3] | ||
| Company |
Omeros, Seattle, WA
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Mannan-binding lectin serine protease-2 (MASP2) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03205995) Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome (aHUS). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.